Prophylaxis of Iodinated Contrast Media-Induced Nephropathy

Idé, Jean-Marc; Lancelot, Eric; Pinès, Emmanuelle; Corot, Claire

doi:10.1097/01.rli.0000101483.60710.2c

Cited by 40 publications

(4 citation statements)

References 127 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other side, the quantity of Au within the AuNCs adequately permits a certain percentage of X-ray transmittance for the appreciation of the hollow structure. With 2.5-fold better contrast per unit weight than standard agents [85] , preliminary studies highlight the potential superiority of gold nanostructures. .…”

Section: Internalization Of Auncs By Melanoma Spheroids and Their Via...mentioning

confidence: 99%

Multiphoton imaging of melanoma 3D models with plasmonic nanocapsules

et al. 2022

View full text Add to dashboard Cite

Section: Internalization Of Auncs By Melanoma Spheroids and Their Via...mentioning

confidence: 99%

Multiphoton imaging of melanoma 3D models with plasmonic nanocapsules

et al. 2022

View full text Add to dashboard Cite

“…It is now widely acknowledged that high-osmolality CM (ionic) are more nephrotoxic than low-osmolality contrast media (LOCM), ionic or nonionic, in at-risk patients [5]. However, whether there are differences in safety among the various CM, particularly with regard to nephrotoxicity, remains controversial.…”

Section: Introductionmentioning

confidence: 99%

Renal safety in pediatric imaging: randomized, double-blind phase IV clinical trial of iobitridol 300 versus iodixanol 270 in multidetector CT

et al. 2011

View full text Add to dashboard Cite

BackgroundIt is debated whether iso-osmolar and low-osmolar contrast media are associated with different incidences of contrast medium-induced nephropathy (CIN) in patients with renal insufficiency.ObjectiveTo compare the incidence of CIN in children undergoing contrast-enhanced multidetector computer tomography (MDCT) with intravenous injection of low-osmolar (iobitridol, Xenetix® 300) or an iso-osmolar (iodixanol, Visipaque® 270) iodinated contrast medium.Materials and methodsOne hundred forty-six children with normal renal function were included in this multicenter trial and underwent contrast-enhanced MDCT. The primary endpoint was the relative change in creatinine clearance from 48 h pre- to 72 h postcontrast medium administration using a noninferiority analysis in the intent-to-treat (ITT, n = 128) and per protocol (n = 68) populations. Secondary endpoints were incidence of CIN, global image quality, diagnostic efficacy and clinical safety.ResultsIn the ITT population, the noninferiority of iobitridol over iodixanol was demonstrated. CIN incidence was 4.8% (three cases) with iobitridol and 10.6% (seven cases) with iodixanol (not significant). No statistically significant differences were observed for the secondary endpoints.ConclusionComparable satisfactory safety profiles were confirmed for both contrast media, with no significant difference in the incidence of CIN in children with normal renal function.

show abstract

“…Generally, RAASi treatment reduces the blood ow of the glomerulus by lowering blood pressure and dilating efferent arterioles [23,24]. Contrast media also reduces the blood ow of the glomerulus through vasoconstriction [25][26][27].…”

Section: Discussionmentioning

confidence: 99%

Association Between Dose Reduction Of Renin-Angiotensin-Aldosterone System Inhibitors Before Coronary Artery Angiography And Acute Kidney Injury: A Propensity Matched Study

Hashimoto

Takeuchi

Kawakami

2022

Preprint

View full text Add to dashboard Cite

Background: Acute kidney injury (AKI), which is commonly observed in hospitalized patients, increases mortality. Although renin-angiotensin-aldosterone system inhibitors (RAASis) and coronary artery angiography (CAG) are reported to be risk factors for AKI, whether dose reduction of RAASis can prevent AKI after CAG remains unknown. The objective of this study was to investigate the association between dose reduction of RAASis and AKI.Methods: In this retrospective propensity score (PS)-matched cohort of patients with an estimated glomerular filtration rate (eGFR) of 15-60 ml/min/1.73 m2 who were prescribed RAASis, we examined the impact of dose reduction of RAASis on the development of AKI after CAG with the RWD database, which includes 20 million patients from 190 hospitals in Japan. The exposure of interest was the presence of a dose reduction in RAASis within the 3 days before CAG was performed. The propensity score was derived from 19 baseline characteristics using a logistic regression model.Results: We identified 3,289 patients who were prescribed RAASis at least one month before admission and underwent CAG. Six hundred seventy-four patients had a dose reduction 3 days prior to undergoing CAG, and 2,640 patients did not. AKI was observed in 42 (4.7%) patients in the reduction group and 121 (5.1%) patients in the control group. There was no significant difference in the primary outcome between the two groups in the PS-matched cohort (OR: 1.00, 95% CI: 0.69-1.47).Conclusions: A reduction in the dose of RAASis did not prevent the development of AKI among patients undergoing CAG.

show abstract

Prophylaxis of Iodinated Contrast Media-Induced Nephropathy

Cited by 40 publications

References 127 publications

Multiphoton imaging of melanoma 3D models with plasmonic nanocapsules

Multiphoton imaging of melanoma 3D models with plasmonic nanocapsules

Renal safety in pediatric imaging: randomized, double-blind phase IV clinical trial of iobitridol 300 versus iodixanol 270 in multidetector CT

Association Between Dose Reduction Of Renin-Angiotensin-Aldosterone System Inhibitors Before Coronary Artery Angiography And Acute Kidney Injury: A Propensity Matched Study

Contact Info

Product

Resources

About